Skip to main content

Table 5 Estimation of MCID estimates in mRSS using Patient Global Assessment anchor for all participants

From: Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II)

Patient Global Assessment N Unadjusted mean Effect size
Mean 95% LCL 95% UCL
Overall
 Change ≤ − 50 8 − 3.75 − 7.69 0.19 − 0.35
 −20 ≥ change > − 50 (MCID estimate for improvement) 35 − 4.06 − 6.66 − 1.45 − 0.38
 − 20 < change < 20 123 − 2.94 − 3.92 − 1.96 − 0.27
 20 ≤ change < 50 23 − 0.17 − 2.71 2.36 − 0.02
 Change ≥ 50 6 1.5 − 2.94 5.94 0.14
Diffuse SSc
 Change ≤ − 50 5 − 5.60 − 11.85 0.65 − 0.58
 −20 ≥ change > − 50 (MCID estimate for improvement) 26 − 5.12 − 8.48 − 1.75 − 0.53
 − 20 < change < 20 69 − 5.16 − 6.57 − 3.74 − 0.54
 20 ≤ change < 50 16 − 0.56 − 4.25 3.12 − 0.06
 Change ≥ 50 2 6.50 − 25.27 38.27 0.68
Limited SSc
 Change ≤ − 50 3 − 0.67 − 5.84 4.50 − 0.19
 − 20 ≥ change > − 50 (MCID estimate for improvement) 9 − 1.00 − 3.72 1.72 − 0.28
 − 20 < change < 20 54 − 0.11 − 0.98 0.76 − 0.03
 20 ≤ change < 50 7 0.71 − 1.40 2.83 0.20
 Change ≥ 50 4 − 1.00 − 2.30 0.30 − 0.28
  1. LCL lower confidence limit, MCID minimal clinically important difference, mRSS modified Rodnan Skin Score, SSc systemic sclerosis, UCL upper confidence limit